ProMIS Neurosciences’Â Alzheimer’s therapy PMN310Â attacks toxic forms of a protein linked to the disease but not normal forms, a…
Articles by Patricia Inacio, PhD
Pain Therapeutics’Â Alzheimer’s therapy PTI-125 was safe, and patients tolerated it well, a Phase 1 clinical trial shows. The therapy…
BAN2401, an investigational anti-amyloid beta antibody therapy for Alzheimer’s disease, has failed to reach the primary endpoint of a Phase 2…
Giving mice with Alzheimer’s a canola oil-rich diet for six months led to their memory and learning ability worsening, a…
Immungenetics AG is conducting a Phase 2 proof-of-concept clinical trial to investigate whether thiethylperazine — a treatment for…
Researchers in Wisconsin are looking for veterans with a family history of Alzheimer’s disease to determine whether fish oil can…
The National Institutes of Health (NIH) awarded a $4 million, five-year grant to a project that will investigate —…
As the number of Americans with Alzheimer’s disease continues to soar, the Global Alzheimer’s Platform (GAP) Foundation is establishing…
Probiodrug‘s PQ912Â decreased markers of inflammation and damage in the nerve cell connections of Alzheimer’s patients, according to a Phase…
An antibody therapy that ProMIS Neurosciences is developing for Alzheimer’s formed a bond with only the harmful forms of amyloid beta…